30/06/2016 08:12:46 1-888-992-3836 (toll free) Free Membership Login

Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
06/24/201611:44AMPRNUSMylan Launches Generic Avodart® Capsules
Mylan Launches Generic Avodart® Capsules PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 24, 2016 HERTFORDSHIRE, England and PITTSBURGH, June 24, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart®... More...>>
06/23/201611:22AMPRNUSMylan Donates €1 Million to the Princess Máxima Center for Pediatric Oncology
Mylan Donates €1 Million to the Princess Máxima Center for Pediatric Oncology PR Newswire HERTFORDSHIRE, England, PITTSBURGH, and UTRECHT, Netherlands, June 23, 2016 HERTFORDSHIRE, England, PITTSBURGH, and UTRECHT, Netherlands, June 23, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), one of the world's leading... More...>>
06/20/20169:54AMPRNUSAttorney General Rejects VEB's Request Regarding Mylan Shareholder Approval of Meda Transaction
Attorney General Rejects VEB's Request Regarding Mylan Shareholder Approval of Meda Transaction PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, June 20, 2016 HERTFORDSHIRE, England, and PITTSBURGH, June 20, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the Attorney General of the Netherlands... More...>>
06/17/20168:00AMPRNUSDrugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma PR Newswire NEW YORK, June 17, 2016 NEW YORK, June 17, 2016 /PRNewswire/ -- On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish... More...>>
06/16/20164:35PMPRNUSMylan to Commence Meda Offer on June 17
Mylan to Commence Meda Offer on June 17 PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 16, 2016 Mylan's Offer Document Approved and Published HERTFORDSHIRE, England and PITTSBURGH, June 16, 2016 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly... More...>>
06/16/20164:35PMPRNUSMylan to Commence Meda Offer on June 17
Mylan to Commence Meda Offer on June 17 Mylan's Offer Document Approved and Published PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, June 16, 2016 HERTFORDSHIRE, England, and PITTSBURGH, June 16, 2016 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly... More...>>
06/15/20161:47PMPRNUSMylan Completes Acquisition of Renaissance's Leading Topicals-Focused Specialty and Generics Business
Mylan Completes Acquisition of Renaissance's Leading Topicals-Focused Specialty and Generics Business PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 15, 2016 HERTFORDSHIRE, England and PITTSBURGH, June 15, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has successfully completed the... More...>>
06/03/20166:00PMDJNStudy Finds Mylan's 'Biosimilar' Drug Comparable to Roche Cancer Medicine
CHICAGO—Researchers said a drug being developed by Mylan Pharmaceuticals Inc. proved comparable to Roche Holding AG's Herceptin in a clinical trial, a new milestone in the effort to bring cheaper versions of some of biotechnology's best-known cancer drugs to the market. In a study involving a total of 500... More...>>
06/03/20162:00PMPRNUSMylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Me...
Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting HERITAGE Study Shows Comparable Efficacy, Safety and Immunogenicity to Branded Trastuzumab in HER2-Positive Metastatic Breast Cancer Patients PR Newswire HERTFORDSHIRE, England, PITTSBURGH... More...>>
06/03/201610:56AMPRNUSMylan Launches Generic Cleocin® Solution
Mylan Launches Generic Cleocin® Solution PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 3, 2016 HERTFORDSHIRE, England and PITTSBURGH, June 3, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Clindamycin Palmitate Hydrochloride for Oral Solution USP, 75 mg/5 mL, which is... More...>>
06/02/20167:30AMPRNUSMylan Launches Generic Vidaza® Injection
Mylan Launches Generic Vidaza® Injection PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 2, 2016 HERTFORDSHIRE, England and PITTSBURGH, June 2, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's... More...>>
06/02/20167:00AMPRNUSMylan Launches Generic Rythmol® Sustained-Release Capsules
Mylan Launches Generic Rythmol® Sustained-Release Capsules PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 2, 2016 HERTFORDSHIRE, England and PITTSBURGH, June 2, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg... More...>>
06/01/201611:42AMPRNUSMylan Launches First Generic of Doxycycline Hyclate Delayed-Release Tablets, 50 mg
Mylan Launches First Generic of Doxycycline Hyclate Delayed-Release Tablets, 50 mg - Company awarded 180 days marketing exclusivity - PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 1, 2016 HERTFORDSHIRE, England and PITTSBURGH, June 1, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S... More...>>
06/01/201610:15AMPRNUSMylan Launches First Generic of Nuvigil® Tablets
Mylan Launches First Generic of Nuvigil® Tablets - Company awarded 180 days marketing exclusivity - PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 1, 2016 HERTFORDSHIRE, England and PITTSBURGH, June 1, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Armodafinil Tablets... More...>>
05/31/20165:24PMPRNUSMylan Announces Pricing of Senior Notes
Mylan Announces Pricing of Senior Notes PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 31, 2016 HERTFORDSHIRE, England and PITTSBURGH, May 31, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the pricing of a private placement of $6.5 billion aggregate principal amount of senior notes, comprised... More...>>
05/26/201611:00AMPRNUSMylan to Present at Goldman Sachs 37th Annual Global Healthcare Conference
Mylan to Present at Goldman Sachs 37th Annual Global Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 26, 2016 HERTFORDSHIRE, England and PITTSBURGH, May 26, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) a leading global pharmaceutical company, today announced that the Company will present... More...>>
05/23/20167:30AMPRNUSMylan Launches First Generic Doryx® Delayed-Release Tablets, 200 mg
Mylan Launches First Generic Doryx® Delayed-Release Tablets, 200 mg - Company awarded 180 days marketing exclusivity - PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 23, 2016 HERTFORDSHIRE, England and PITTSBURGH, May 23, 2016 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL, TASE: MYL) today announced the U.S. launch... More...>>
05/17/20165:45PMPRNUSMylan Updates Timetable for Commencement of Acceptance Period for Offer for Meda
Mylan Updates Timetable for Commencement of Acceptance Period for Offer for Meda PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 17, 2016 Closing of Offer Continues to be Expected in Q3 2016 HERTFORDSHIRE, England and PITTSBURGH, May 17, 2016 /PRNewswire/ -- The Offer is not being made, and this press release may... More...>>
05/17/20165:45PMPRNUSMylan Updates Timetable for Commencement of Acceptance Period for Offer for Meda
Mylan Updates Timetable for Commencement of Acceptance Period for Offer for Meda Closing of Offer Continues to be Expected in Q3 2016 PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 17, 2016 HERTFORDSHIRE, England and PITTSBURGH, May 17, 2016 /PRNewswire/ -- The Offer is not being made, and this press release may... More...>>
05/13/20169:00AMPRNUSMylan to Acquire Renaissance's Leading Topicals-Focused Specialty and Generics Business
Mylan to Acquire Renaissance's Leading Topicals-Focused Specialty and Generics Business Transaction Immediately Accretive to Adjusted Diluted EPS PR Newswire HERTFORDSHIRE, England and PITTSBURGH, May 13, 2016 HERTFORDSHIRE, England and PITTSBURGH, May 13, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V:us D:20160630 12:12:48